CStone Pharma-B (02616) to Unveil Phase I Dose Escalation Clinical Data for PD-1/VEGF/CTLA-4 Triple Antibody and Latest Research Design for ROR1 ADC

Stock News

Oct 13, 2025

CStone Pharma-B (02616) announced that the 2025 European Society for Medical Oncology (ESMO) Annual Congress will be held from October 17-21, 2025, in Berlin, Germany. Abstracts for the company's core clinical pipeline CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody) ongoing Phase I dose escalation clinical data and CS5001 (ROR1 antibody-drug conjugate [ADC]) ongoing Phase Ib clinical study design have been published on ESMO's official website.

The CS2009 abstract covers only Phase I baseline data from 9 patients as of May 8, 2025 (abstract submission deadline), designed to meet ESMO's abstract submission requirements. At the upcoming ESMO congress, CStone Pharma will present preliminary data from CS2009's Phase I dose escalation clinical study in approximately 70 advanced solid tumor patients in poster format. This will mark the world's first clinical data publication for a PD-1/VEGF/CTLA-4 tri-specific antibody to date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106947223"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106947223\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106947223?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106947223","market":"us","top_or_hot":-1,"title":"CStone Pharma-B (02616) to Unveil Phase I Dose Escalation Clinical Data for PD-1/VEGF/CTLA-4 Triple Antibody and Latest Research Design for ROR1 ADC","media":"Stock News","content":"<p>CStone Pharma-B (02616) announced that the 2025 European Society for Medical Oncology (ESMO) Annual Congress will be held from October 17-21, 2025, in Berlin, Germany. Abstracts for the company's core clinical pipeline CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody) ongoing Phase I dose escalation clinical data and CS5001 (ROR1 antibody-drug conjugate [ADC]) ongoing Phase Ib clinical study design have been published on ESMO's official website.</p>\n<p>The CS2009 abstract covers only Phase I baseline data from 9 patients as of May 8, 2025 (abstract submission deadline), designed to meet ESMO's abstract submission requirements. At the upcoming ESMO congress, CStone Pharma will present preliminary data from CS2009's Phase I dose escalation clinical study in approximately 70 advanced solid tumor patients in poster format. This will mark the world's first clinical data publication for a PD-1/VEGF/CTLA-4 tri-specific antibody to date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharma-B (02616) to Unveil Phase I Dose Escalation Clinical Data for PD-1/VEGF/CTLA-4 Triple Antibody and Latest Research Design for ROR1 ADC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharma-B (02616) to Unveil Phase I Dose Escalation Clinical Data for PD-1/VEGF/CTLA-4 Triple Antibody and Latest Research Design for ROR1 ADC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-13 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CStone Pharma-B (02616) announced that the 2025 European Society for Medical Oncology (ESMO) Annual Congress will be held from October 17-21, 2025, in Berlin, Germany. Abstracts for the company's core clinical pipeline CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody) ongoing Phase I dose escalation clinical data and CS5001 (ROR1 antibody-drug conjugate [ADC]) ongoing Phase Ib clinical study design have been published on ESMO's official website.</p>\n<p>The CS2009 abstract covers only Phase I baseline data from 9 patients as of May 8, 2025 (abstract submission deadline), designed to meet ESMO's abstract submission requirements. At the upcoming ESMO congress, CStone Pharma will present preliminary data from CS2009's Phase I dose escalation clinical study in approximately 70 advanced solid tumor patients in poster format. This will mark the world's first clinical data publication for a PD-1/VEGF/CTLA-4 tri-specific antibody to date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"","article_id":"1106947223","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106947223","pubTimestamp":1760314460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CStone Pharma-B (02616) announced that the 2025 European Society for Medical Oncology (ESMO) Annual Congress will be held from October 17-21, 2025, in Berlin, Germany. Abstracts for the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B","BK1161":"生物科技","BK4231":"零售房地产信托","PD":"PagerDuty, Inc.","BK4080":"零售业房地产投资信托","BK4023":"应用软件","ADC":"艾格里房产","BK1574":"生物医药B类股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC"},"translate_title":"基石药业-B(02616)公布PD-1/VEGF/CTLA-4三抗I期剂量递增临床数据及ROR1 ADC最新研究设计","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1,"PD":1,"ADC":1},"content_text":"CStone Pharma-B (02616) announced that the 2025 European Society for Medical Oncology (ESMO) Annual Congress will be held from October 17-21, 2025, in Berlin, Germany. Abstracts for the company's core clinical pipeline CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody) ongoing Phase I dose escalation clinical data and CS5001 (ROR1 antibody-drug conjugate [ADC]) ongoing Phase Ib clinical study design have been published on ESMO's official website.\nThe CS2009 abstract covers only Phase I baseline data from 9 patients as of May 8, 2025 (abstract submission deadline), designed to meet ESMO's abstract submission requirements. At the upcoming ESMO congress, CStone Pharma will present preliminary data from CS2009's Phase I dose escalation clinical study in approximately 70 advanced solid tumor patients in poster format. This will mark the world's first clinical data publication for a PD-1/VEGF/CTLA-4 tri-specific antibody to date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}